Skip to main content
Oxurion NV logo

Oxurion NV — Investor Relations & Filings

Ticker · OXUR ISIN · BE0974487192 LEI · 549300VWY8KVDFKLDM59 BR Professional, scientific and technical activities
Open in API
Filings indexed 1,031 across all filing types
Latest filing 2011-11-08 Interim / Quarterly Rep…
Country BE Belgium
Listing BR OXUR

About Oxurion NV

https://oxurion.com/

Oxurion NV is a company focused on acquiring majority stakes in European pharmaceutical subcontractors. Its strategy is to build an integrated group of contract service providers to support healthcare stakeholders. A key asset in its portfolio is a majority stake in Axiodis CRO, a contract research organization specializing in biometrics. This investment-based business model represents a strategic pivot from the company's former focus on the internal research and development of therapies for retinal diseases such as Geographic Atrophy (GA) and Age-related Macular Degeneration (AMD).

Recent filings

Filing Released Lang Actions
11_THR_15 Q3 2011 Business Update_FINAL_DU.pdf
Interim / Quarterly Report Classification · 95% confidence The document is a 'Business Update' from ThromboGenics NV, which provides a comprehensive overview of the company's operational progress (clinical trials, regulatory status of ocriplasmine) and financial status (cash position, revenue) for the nine-month period ending September 30, 2011. It contains substantive financial data and management analysis rather than being a mere announcement of a report or a short press release. Therefore, it qualifies as an Interim/Quarterly Report. 9M 2011
2011-11-08 Dutch
Half Year Financial Report EN.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim Financial Report – First Half results 2011' and contains detailed unaudited consolidated financial statements, including the statement of financial position and statement of comprehensive income for the six-month period ending June 30, 2011. It also includes business highlights and management commentary. As it provides comprehensive financial data for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report. H1 2011
2011-08-25 English
Financieel verslag 30-06-2011.pdf
Interim / Quarterly Report Classification · 100% confidence The document is a 'Tussentijds Financieel Verslag' (Interim Financial Report) for the period ending June 30, 2011. It contains detailed unaudited consolidated financial statements (balance sheet, profit and loss account), business highlights, and management commentary on product pipelines (Ocriplasmine, TB-402, etc.). Since it provides substantive financial data and analysis for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report. H1 2011
2011-08-25 Dutch
ThromboGenics on track
Regulatory Filings Classification · 95% confidence The document is a press release dated August 9, 2011, providing an update on regulatory filing plans for the drug ocriplasmin, stating the company expects to file with the EMA in the next two months and with the FDA before year-end. It discusses clinical trial data presentations and pre-commercialization activities. This is a general corporate update regarding product development and regulatory milestones, not a formal financial report (like 10-K or IR), a transcript (CT), or a specific shareholder action (like DIV or DVA). Since it is an announcement updating investors on progress and future plans, it fits best under the general 'Regulatory Filings' (RNS) category as a miscellaneous corporate announcement, or potentially 'Capital/Financing Update' (CAP) if the filing itself was a financing event, but here it is purely operational/regulatory progress. Given the options, RNS serves as the best general category for non-standard corporate news updates that don't fit the highly specific financial or governance codes. It is short and announces progress rather than attaching a full report.
2011-08-09 English
ThromboGenics op koers
Regulatory Filings Classification · 95% confidence The document is a press release dated August 9, 2011, from ThromboGenics NV, written in Dutch. It provides an update on the progress towards submitting regulatory dossiers (EMA and FDA) for their product, ocriplasmine, and mentions ongoing commercialization preparations and positive Phase III study results presented at conferences. This type of announcement, detailing operational progress, regulatory milestones, and future expectations, is characteristic of an Earnings Release (ER) or a general corporate update. Since it is not a full financial report (10-K or IR), a transcript (CT), or a specific legal/governance filing, and it focuses on key business updates rather than just a dividend or management change, 'ER' (Earnings Release) is the most appropriate classification for a significant operational update, even if it's not strictly tied to a quarterly earnings period in the text itself. Given the context of a bio-pharma company providing a major product update, it functions as a material corporate announcement.
2011-08-09 Dutch
11_TG_XX Transparantiemelding.pdf
Major Shareholding Notification Classification · 98% confidence The document is a press release from ThromboGenics NV dated June 25, 2011, announcing the receipt of a transparency declaration from a major shareholder (Baker Brothers Life Sciences LP) regarding a change in shareholding percentage below the 5% threshold, as required by Belgian transparency legislation. This type of filing, which reports changes in significant share ownership, directly corresponds to the definition of 'Major Shareholding Notification' (MRQ). Although it is a regulatory announcement, it is highly specific to share ownership changes, making MRQ a better fit than the general 'RNS' fallback. The document length (4633 chars) is substantial enough to be the primary announcement itself, not just a brief notice of publication.
2011-06-27 Dutch

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.